Back to mobile site

BioNTech SE (BNTX) Reports Q1 EPS of EUR4.39

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

May 10, 2021 7:11 AM EDT

BioNTech SE (NASDAQ: BNTX) reported Q1 EPS of EUR4.39, versus (EUR0.24) reported last year. Revenue for the quarter came in at EUR2.05 billion, versus EUR27.7 million reported last year.

Update on current signed COVID-19 vaccine order book:

Estimated COVID-19 vaccine revenues to BioNTech upon delivery of currently signed supply contracts of ~1.8 billion doses is ~€12.4 billion. This revenue estimate reflects:
  • Expected revenues from direct COVID-19 vaccine sales to customers in BioNTech’s territory
  • Expected revenues from sales to collaboration partners of products manufactured by BioNTech
  • Expected sales milestone payments from collaboration partners
  • Expected revenues related to share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territories
Additional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond. Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.

On Track with Previously Stated 2021 Financial Outlook:

Planned Full Year 2021 Expenses and Capex3
R&D expenses€750 million – €850 millionRamp-up of R&D investment in the second half of 2021 and beyond planned to broaden and accelerate pipeline development.
SG&A expensesUp to €200 million
Capital expenditures€175 million – €225 million
Estimated Full Year 2021 Tax Assumptions
German tax group corporate tax rate~31%

The full interim unaudited condensed consolidated financial statements can be found in BioNTech’s Quarterly Report on Form 6-K, filed today with the SEC and available at https://www.sec.gov/.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings